Patent classifications
A61K31/727
COMPOSITIONS AND METHODS OF TREATING COVID-19 WITH HEPARIN OR OTHER NEGATIVELY CHARGED MOLECULES
Compositions and methods of treating COVID-19 are disclosed. The compositions comprise heparin and/or one or more other negatively charged molecules.
COMPOSITIONS AND METHODS OF TREATING COVID-19 WITH HEPARIN OR OTHER NEGATIVELY CHARGED MOLECULES
Compositions and methods of treating COVID-19 are disclosed. The compositions comprise heparin and/or one or more other negatively charged molecules.
COMPOSITIONS AND METHODS FOR RED BLOOD CELL DIFFERENTIATION
The invention described herein is directed to compositions and methods for inducing red blood cell (RBC) differentiation. Additionally, provided herein are methods of treating a subject in need thereof by administering the induced RBC described herein.
COMPOSITIONS AND METHODS FOR RED BLOOD CELL DIFFERENTIATION
The invention described herein is directed to compositions and methods for inducing red blood cell (RBC) differentiation. Additionally, provided herein are methods of treating a subject in need thereof by administering the induced RBC described herein.
COMPOSITIONS AND METHODS FOR RED BLOOD CELL DIFFERENTIATION
The invention described herein is directed to compositions and methods for inducing red blood cell (RBC) differentiation. Additionally, provided herein are methods of treating a subject in need thereof by administering the induced RBC described herein.
Delivery device and formulation
The present invention relates to a handheld vibrating mesh nebuliser for delivery of a medicament to the respiratory system in therapy. The present invention also relates to a supply container for loading the nebuliser with liquid medicament. The present invention also relates to a kit for delivery of a medicament to a respiratory system and a method of loading a vibrating mesh nebuliser with liquid medicament from a supply container. The present invention also relates to compositions for use in a method of treatment of a respiratory disease in a patient by therapy.
Delivery device and formulation
The present invention relates to a handheld vibrating mesh nebuliser for delivery of a medicament to the respiratory system in therapy. The present invention also relates to a supply container for loading the nebuliser with liquid medicament. The present invention also relates to a kit for delivery of a medicament to a respiratory system and a method of loading a vibrating mesh nebuliser with liquid medicament from a supply container. The present invention also relates to compositions for use in a method of treatment of a respiratory disease in a patient by therapy.
Delivery device and formulation
The present invention relates to a handheld vibrating mesh nebuliser for delivery of a medicament to the respiratory system in therapy. The present invention also relates to a supply container for loading the nebuliser with liquid medicament. The present invention also relates to a kit for delivery of a medicament to a respiratory system and a method of loading a vibrating mesh nebuliser with liquid medicament from a supply container. The present invention also relates to compositions for use in a method of treatment of a respiratory disease in a patient by therapy.
Heparanase Inhibitor as Anti-Viral and Immunomodulatory Therapy
A method of treating an RNA virus infection in a subject in need that includes administering a therapeutically effective amount of a heparanase inhibitor. The RNA virus includes SARS-CoV-1, SARS-CoV-2, HTLV-1, HIV-1, and any combination thereof. The heparanase inhibitor includes heparin, a heparin mimetic, or any combination thereof. In some aspects, the heparanase inhibitor is Roneparstat. In some aspects, the administration of the therapeutically effective amount of the heparanase inhibitor results in the inhibition of infection by the RNA virus and associated inflammatory cytokine production.
Heparanase Inhibitor as Anti-Viral and Immunomodulatory Therapy
A method of treating an RNA virus infection in a subject in need that includes administering a therapeutically effective amount of a heparanase inhibitor. The RNA virus includes SARS-CoV-1, SARS-CoV-2, HTLV-1, HIV-1, and any combination thereof. The heparanase inhibitor includes heparin, a heparin mimetic, or any combination thereof. In some aspects, the heparanase inhibitor is Roneparstat. In some aspects, the administration of the therapeutically effective amount of the heparanase inhibitor results in the inhibition of infection by the RNA virus and associated inflammatory cytokine production.